Blog
China Autoinjectors Market: Company Analysis of 8 Key Players, Product Mapping and Competitive Landscape
Company Analysis | Medical Devices | China
By Global Data Route Analytics Research Team · Published 26 September 2026 · 12 min read
The China autoinjectors market is one of the fastest-moving corners of the country's medical device industry. GLP-1 drugs such as semaglutide, tirzepatide and liraglutide, a strong domestic biologics pipeline and the shift toward self-injection at home have created real demand for pen injectors, prefilled syringe (PFS) based autoinjectors and smart electronic pens.
In this China autoinjectors market company analysis, we profile the eight leading Chinese autoinjector manufacturers and suppliers active in this market. For each one we look at the company background, product portfolio, recent developments, financial snapshot and contact details, and then map where each company sits in the competitive landscape.
Key findings
- WEGO Prefills is the scale leader. It holds more than 50% of China's prefilled syringe market, and in 2026 it was folded into Weigao Blood Purification in an RMB 8.51 billion share deal.
- GLP-1 is the main battleground. Seven of the eight companies market pens or autoinjectors for semaglutide, tirzepatide or liraglutide.
- Newer specialists such as Shenzhen Lingrui, HealthyTree, Healing Biotech and Enjosim compete on patented platforms, FTO (freedom-to-operate) claims and OEM/ODM flexibility.
- Emerging entrants such as LBE Pharma (epinephrine autoinjector, dual-chamber PFS) and Nextech-X (smart electronic pen, COP syringes) are widening the product mix.
RMB 8.51 bn
WEGO Prefills acquisition (2026)
50%+
WEGO share of China's PFS market
7 of 8
Companies targeting GLP-1 pens
45+
Official company sources analysed
Who Are the Top Autoinjector Manufacturers in China?
The top autoinjector manufacturers and suppliers in China are:
- Shandong WEGO Prefills: market leader in prefilled syringes, autoinjectors and pen injectors
- Jiangsu Delfu Medical Device: established maker of autoinjector and insulin pens since 1995
- Enjosim Medical: pen and two-step autoinjector specialist with multi-country registrations
- HealthyTree Medical Device: GLP-1 autoinjectors plus assembly machines
- Shenzhen Lingrui Biotechnology: IP-led GLP-1 autoinjector and smart pen platforms
- Shenzhen Healing Biotech: one-stop autoinjector, pen and assembly-line supplier
- Nextech-X (Hangzhou Qiantang Longyue): smart electronic pens and COP prefilled syringes
- LBE Pharma Tech: epinephrine autoinjector, dual-chamber PFS and CDMO
Table of Contents
- Company Overview at a Glance
- Product Mapping Analysis
- Detailed Company Analysis
- Recent Developments, Mergers & Acquisitions Timeline
- Competitive Landscape Analysis
- Vendor Landscape
- Competitive Environment
- Merger & Acquisition Analysis
- Strategy Framework
- Heat Map Analysis
- Frequently Asked Questions
- Conclusion
Company Overview at a Glance
The table below summarises each company's location, age and scale. The figures come from company websites and B2B profiles; figures marked * are self-reported.
| Company | HQ | Founded | Positioning | Scale indicator |
|---|---|---|---|---|
| Shandong WEGO Prefills | Weihai, Shandong | 2005 | Market leader in PFS, autoinjector and pen injector; part of WEGO Group | H1 2025 revenue RMB 939M |
| Jiangsu Delfu Medical Device | Changzhou, Jiangsu | 1995 | Established diabetes device maker; 15+ autoinjector pen variants | US$50–60M annual sales*; 680+ staff |
| Enjosim Medical | Shanghai HQ, Wuxi factory | Not disclosed | Pen and autoinjector specialist; 180 pen models, 34 core patents | ~100M pens/year capacity* |
| HealthyTree Medical Device | Suzhou / Hangzhou | Not disclosed | Autoinjector and pen specialist plus assembly equipment | 250–499 employees |
| Shenzhen Lingrui Biotechnology | Shenzhen, Guangdong | Not disclosed | GLP-1 focused autoinjector and smart pen platforms | US$10–50M revenue*; 100–249 staff |
| Shenzhen Healing Biotech | Shenzhen, Guangdong | Not disclosed | Autoinjector, pen and assembly-line supplier; OEM/ODM | 100M units/year target* |
| Nextech-X (Hangzhou Qiantang Longyue) | Hangzhou, Zhejiang | 2021 | Smart electronic pen, GLP-1 pen, COP PFS | 2 FDA 510(k) clearances |
| LBE Pharma Tech | Shanghai & Fuzhou | 2023 | Epinephrine autoinjector, dual-chamber PFS, CDMO | 50–99 employees |
Product Mapping Analysis
This matrix maps each company's portfolio across the main autoinjector and pen injector categories, based on the product pages on each company's website.
| Company | Single-dose autoinjector | Multi-dose / cartridge pen | Disposable pen | Reusable pen | Smart / electronic | PFS, cartridge & safety parts | Assembly lines / CDMO |
|---|---|---|---|---|---|---|---|
| WEGO Prefills | ✓ | ✓ | ✓ | – | – | ✓ | – |
| Delfu Medical | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | – |
| Enjosim Medical | ✓ | ✓ | ✓ | ✓ | – | ✓ | – |
| HealthyTree | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Shenzhen Lingrui | ✓ | ✓ | – | ✓ | ✓ | ✓ | ✓ |
| Healing Biotech | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Nextech-X | ✓ | ✓ | ✓ | – | ✓ | ✓ | – |
| LBE Pharma | ✓ | – | – | – | – | ✓ | ✓ |
Takeaway: HealthyTree and Healing Biotech offer the widest “device plus assembly line” packages, WEGO leads on primary containers, and LBE Pharma is the only company here combining an emergency autoinjector with fill-finish CDMO services.
Need full product benchmarking for every autoinjector supplier in China?
Get Free Sample →Detailed Company Analysis
The profiles below are ordered roughly by scale, from the market leader to newer entrants.
Want deeper profiles, market shares and forecasts?
Speak with our analysts about company benchmarking and segment data for the China autoinjectors market.
Inquire Before BuyingRecent Developments, Mergers & Acquisitions Timeline
May 2023
HealthyTree wins Functionality Gold and Cost Effective Silver at PMEC China.
Oct 2023
LBE Pharma Tech founded to develop drug-device combinations and CDMO services.
Sep 2024
WEGO Prefills autoinjector registered with Akeso's AK102 antibody.
Late 2024
Healing Biotech exhibits autoinjectors and pens at CPHI Middle East.
Oct 2025
LBE Pharma showcases its epinephrine autoinjector at CPHI Europe, Frankfurt.
Jan 2026
Weigao Blood Purification announces RMB 8.511 billion all-share acquisition of WEGO Prefills.
Apr 2026
Enjosim receives market approval for two disposable pen injectors.
Sep 2026
WEGO Prefills acquisition completed; it becomes a wholly owned subsidiary.
Competitive Landscape Analysis
Based on scale, portfolio breadth and regulatory progress, the eight companies fall into three groups:
Tier 1: Scale leaders
WEGO Prefills, Jiangsu Delfu
Large manufacturing bases, proven revenue and broad customer networks. WEGO dominates primary containers; Delfu brings decades of diabetes device exports.
Tier 2: Platform specialists
Enjosim, HealthyTree, Shenzhen Lingrui, Healing Biotech
Dedicated pen and autoinjector platforms with patents and FTO claims, OEM/ODM flexibility and, in some cases, assembly equipment. They compete hard for GLP-1 generic customers.
Tier 3: Emerging innovators
Nextech-X, LBE Pharma
Younger companies bringing niche technology such as smart electronic pens, COP syringes, dual-chamber PFS and emergency epinephrine autoinjectors.
What will decide the winners?
- GLP-1 patent expiries: generic semaglutide and liraglutide launches will reward companies with ready, FTO-cleared pen platforms.
- Registration with the drug: autoinjectors are approved together with the medicine, so co-registrations like WEGO–Akeso are a strong competitive moat.
- Vertical integration: owning the syringe or cartridge, the device and assembly reduces cost and supply risk.
- International approvals: FDA, CE and emerging-market registrations separate export-ready suppliers from local-only players.
Vendor Landscape
The vendor landscape groups each company by business model, core offering, target therapies, geographic reach and credentials.
| Company | Vendor Type | Core Offering | Target Therapies | Geographic Reach | Credentials |
|---|---|---|---|---|---|
| WEGO Prefills | Integrated Leader | PFS, autoinjector, pen injector, cartridges | Biologics, insulin, GLP-1, vaccines | China #1 in PFS; global #5 | Registered with Akeso AK102 |
| Delfu Medical | Established OEM | 15+ autoinjector pens, insulin pens, pumps, CGM | Diabetes, GLP-1, HGH | 60–70% exported worldwide | ISO 13485, CE, SFDA |
| Enjosim Medical | Platform Specialist | 2-step autoinjector, disposable & reusable pens | GLP-1, insulin, HGH, FSH, biologics | Multi-country registrations | ISO 13485, MDSAP, CE, CDSCO, ANVISA, FDA DMF |
| HealthyTree | Device + Equipment | Single/multi-dose autoinjectors, pens, assembly machines | GLP-1 (semaglutide, tirzepatide, liraglutide) | Europe, Middle East, Asia, Africa, LatAm | CE, ISO 9001, ISO 11608 design |
| Shenzhen Lingrui | Platform Specialist | PFS autoinjector, LR001 multi-dose pen, smart pen | GLP-1 weight loss | Europe, Middle East, Americas | ISO 13485 (claimed), FTO analysis |
| Healing Biotech | One-stop Supplier | Disposable autoinjector, Maggic pen, assembly lines | Insulin, GLP-1, RA, MS, epinephrine | North America, China | SGS-audited, FTO in China & US |
| Nextech-X | Emerging Innovator | Smart e-pen, GLP-1 pen, COP PFS | GLP-1, ophthalmic, vaccines | Global via CPHI | ISO 13485, 2 FDA 510(k) |
| LBE Pharma | Drug-Device + CDMO | LBE-01 epinephrine autoinjector, dual-chamber PFS | Anaphylaxis, CNS | China; CPHI Europe | GMP (PIC/S), ISO 9001 |
Competitive Environment
Using Porter's Five Forces, the table below shows how intense competition is in the China autoinjectors market and why.
| Force | Intensity | Market Evidence | Strategic Implication |
|---|---|---|---|
| Competitive Rivalry | High
|
Seven of eight companies target the same GLP-1 pen and autoinjector demand, with overlapping specs (1 mL / 2.25 mL PFS, 3 mL cartridges). | Differentiate via patents, co-registrations and speed to approval. |
| Threat of New Entrants | Medium-High
|
Nextech-X (2021) and LBE Pharma (2023) show new players can enter quickly, but combination-product registration takes time. | Lock in pharma partners early through drug-device co-registration. |
| Bargaining Power of Buyers | High
|
Pharma companies choose from many suppliers, and volume-based procurement squeezes device pricing. | Offer OEM/ODM flexibility, assembly lines and regulatory support. |
| Bargaining Power of Suppliers | Medium
|
Primary containers are concentrated: WEGO holds more than 50% of China's PFS market. | Secure container supply or integrate vertically. |
| Threat of Substitutes | Low-Medium
|
Vials with syringes and emerging oral GLP-1s are alternatives, but self-injection convenience favours pens. | Invest in smart, connected and easy-to-use devices. |
Merger & Acquisition Analysis
Deal activity among these eight companies is still limited, but one landmark transaction and several strategic tie-ups show the direction of the market.
| Date | Deal / Parties | Type | Value | Strategic Rationale | Market Impact |
|---|---|---|---|---|---|
| Jan 2026 (announced) Sep 2026 (completed) |
Weigao Blood Purification (603014.SH) acquires 100% of WEGO Prefills | Acquisition | RMB 8.511 bn (271,997,882 new shares) |
Moves China's #1 PFS maker into an A-share listed vehicle; Weigao Group's stake in Blood Purification rises from 23.53% to 52.10%. | Creates a well-funded, listed leader in PFS and autoinjectors. |
| Sep 2024 | WEGO Prefills × Akeso (AK102 antibody) | Co-registration | Undisclosed | Autoinjector registered together with a commercial monoclonal antibody. | Proves domestic devices can reach commercial biologics. |
| Not disclosed | Shenzhen Lingrui × Suzhou HealthyTree | Strategic Partnership | Undisclosed | Joint full industry-chain autoinjector solution covering device and assembly. | Combines IP platform with manufacturing equipment for GLP-1 generics. |
| Oct 2025 | LBE Pharma at CPHI Europe | Partnering Drive | n/a | Actively seeking pharma partners for its prefilled epinephrine autoinjector and CDMO services. | Signals future licensing or supply deals. |
Outlook: with many small, privately held specialists competing for the same GLP-1 customers, further consolidation is likely, most probably led by larger groups such as WEGO/Weigao.
Strategy Framework
The framework below shows each company's main strategy, growth levers, key strength and the main risk to watch.
| Company | Core Strategy | Growth Levers | Key Strength | Watch-out |
|---|---|---|---|---|
| WEGO Prefills | Vertical Integration | Container-to-device supply; listed-parent capital; biologic co-registrations | Scale, 50%+ PFS share, profitability | Integration risk after acquisition |
| Delfu Medical | Export-led OEM/ODM | Broad pen range; 20–30% annual capacity growth; global distribution | 30+ years of experience, export network | Few visible partnerships or approvals |
| Enjosim Medical | Regulatory-led Expansion | Multi-country registrations; new commercial pen approvals; trade shows | Strong certifications, 180 pen models | Financials not disclosed |
| HealthyTree | Device + Equipment Bundle | Sells devices and assembly machines; Lingrui partnership | Award-winning design, one-stop package | Mixed location and company data |
| Shenzhen Lingrui | IP-led GLP-1 Focus | FTO-cleared platforms; OEM/ODM; generic GLP-1 wave | Clear GLP-1 branding and IP story | Young company, scale still building |
| Healing Biotech | One-stop Solutions | Devices plus assembly lines; FTO in China and US; 100M-unit target | Very broad catalogue | FDA status not yet confirmed |
| Nextech-X | Tech Innovation | Smart e-pens, COP PFS, ophthalmic and aesthetic niches | FDA track record on accessories | Small facility, limited capacity data |
| LBE Pharma | Niche + CDMO | Epinephrine autoinjector; dual-chamber PFS; fill-finish services | Unique emergency-use focus, regulator attention | No product approval published yet |
Heat Map Analysis
The heat map scores each company from 1 (low) to 5 (high) on seven competitive factors. These are analyst scores based on the public information in this blog; darker cells mean a stronger position.
| Company | Portfolio Breadth | GLP-1 Focus | Mfg. Scale | Regulatory | Global Reach | Partnerships / M&A | Innovation | Total /35 |
|---|---|---|---|---|---|---|---|---|
| WEGO Prefills | 4 | 3 | 5 | 5 | 4 | 5 | 3 | 29 |
| Enjosim Medical | 4 | 5 | 4 | 5 | 4 | 2 | 3 | 27 |
| HealthyTree | 5 | 5 | 3 | 3 | 4 | 3 | 4 | 27 |
| Delfu Medical | 5 | 4 | 4 | 4 | 5 | 1 | 3 | 26 |
| Shenzhen Lingrui | 4 | 5 | 3 | 3 | 3 | 3 | 4 | 25 |
| Healing Biotech | 5 | 4 | 3 | 2 | 3 | 1 | 3 | 21 |
| Nextech-X | 3 | 3 | 2 | 4 | 3 | 1 | 4 | 20 |
| LBE Pharma | 2 | 1 | 2 | 2 | 3 | 2 | 4 | 16 |
Reading the heat map: WEGO Prefills leads on scale, regulatory strength and deal activity. Enjosim and HealthyTree are the strongest private specialists, and Delfu leads on global reach. Nextech-X and LBE Pharma score lower today but stand out on innovation.
Want the complete heat map scoring, market size and forecasts?
Download Sample Report →Frequently Asked Questions
What is the China autoinjectors market?
The China autoinjectors market covers devices that let patients self-inject a pre-measured dose of medicine, including single-dose prefilled syringe (PFS) autoinjectors, multi-dose cartridge pens, disposable and reusable pen injectors and smart electronic pens. Demand is driven by GLP-1 drugs, biologics and home-based care.
Who are the leading autoinjector companies in China?
Key companies include Shandong WEGO Prefills, Jiangsu Delfu Medical Device, Enjosim Medical, HealthyTree Medical Device, Shenzhen Lingrui Biotechnology, Shenzhen Healing Biotech, Nextech-X (Hangzhou Qiantang Longyue Biotechnology) and LBE Pharma Tech.
Which company leads the China prefilled syringe and autoinjector market?
Shandong WEGO Prefills is the leader, with more than 50% of China's prefilled syringe market. In 2026 it became a wholly owned subsidiary of Weigao Blood Purification after an RMB 8.511 billion acquisition.
Why is GLP-1 important for the China autoinjectors market?
GLP-1 drugs such as semaglutide, tirzepatide and liraglutide are delivered by pen injectors or autoinjectors. As more Chinese generic and biosimilar versions launch, demand for locally made, patent-cleared pen platforms is rising sharply.
What are the main types of autoinjectors made in China?
Chinese companies make single-dose autoinjectors for 1 mL and 2.25 mL prefilled syringes, multi-dose autoinjectors and pens using 3 mL cartridges, disposable and reusable pen injectors, smart electronic pens, and emergency epinephrine autoinjectors.
What was the biggest recent M&A deal in the China autoinjectors market?
The biggest deal was Weigao Blood Purification's all-share acquisition of 100% of Shandong WEGO Prefills for RMB 8.511 billion, announced in January 2026 and completed in September 2026.
How can I get the full China autoinjectors market report?
You can download a free sample, ask our analysts a question, or request a discount on the China Autoinjectors Market report.
Conclusion
The China autoinjectors market is no longer led only by imported devices. WEGO Prefills sets the pace on scale and containers, Delfu and Enjosim bring manufacturing depth and regulatory reach, and specialists such as Lingrui, HealthyTree and Healing Biotech are racing to supply the coming wave of GLP-1 generics. Newer players like Nextech-X and LBE Pharma show that innovation in smart pens, dual-chamber systems and emergency autoinjectors is also coming from China. For drug makers, investors and suppliers, tracking these companies' product pipelines and partnerships will be key over the next few years.
Research Methodology & Sources
This analysis is based on each company's official website (About Us, products, contact and news pages), stock exchange filings, regulatory databases and trade-show profiles, reviewed in September 2026. Figures marked as self-reported come from company or B2B listings and have not been independently audited.
- Weigao / WEGO Prefills acquisition (TipRanks)
- HKEX shareholder circular, Jan 2026
- The Paper: WEGO Prefills deal details
- QQ News: acquisition completion
- WEGO Prefills: AK102 co-registration news
- PMEC China: HealthyTree award
- US FDA 510(k) K222718 (Nextech-X)
- US FDA 510(k) K233277 (Nextech-X)
- CPHI Online: HealthyTree profile
- CPHI Online: Shenzhen Lingrui profile
Get the Full China Autoinjectors Market Report
Market size, forecasts, segmentation and in-depth company profiles in one report. See the free sample first, with no obligation.
Download SampleMake an InquiryRequest Discount